Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-2659-5666
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees70
Next Earnings Date2/14/2020 (Estimated)
OptionableNot Optionable
Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions
What is Gamida Cell's stock symbol?
Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."
How were Gamida Cell's earnings last quarter?
Gamida Cell Ltd (NASDAQ:GMDA) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.32. View Gamida Cell's Earnings History.
When is Gamida Cell's next earnings date?
What price target have analysts set for GMDA?
5 analysts have issued 1 year price objectives for Gamida Cell's shares. Their forecasts range from $15.00 to $23.00. On average, they expect Gamida Cell's share price to reach $19.00 in the next year. This suggests a possible upside of 327.0% from the stock's current price. View Analyst Price Targets for Gamida Cell.
What is the consensus analysts' recommendation for Gamida Cell?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell.
Has Gamida Cell been receiving favorable news coverage?
Media stories about GMDA stock have trended negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gamida Cell earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Gamida Cell.
Are investors shorting Gamida Cell?
Gamida Cell saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 33,900 shares, an increase of 11.5% from the July 31st total of 30,400 shares. Based on an average trading volume of 31,400 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.4% of the shares of the stock are sold short. View Gamida Cell's Current Options Chain.
Who are some of Gamida Cell's key competitors?
Some companies that are related to Gamida Cell include Agenus (AGEN), Prevail Therapeutics (PRVL), Tcr2 Therapeutics (TCRR), Adverum Biotechnologies (ADVM), Harpoon Therapeutics (HARP), Replimune Group (REPL), Gritstone Oncology (GRTS), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), La Jolla Pharmaceutical (LJPC), Eiger Biopharmaceuticals (EIGR), LogicBio Therapeutics (LOGC) and PDL BioPharma (PDLI).
What other stocks do shareholders of Gamida Cell own?
Who are Gamida Cell's key executives?
Gamida Cell's management team includes the folowing people:
- Julian Adams, Chief Executive Officer & Director
- Yael Margolin, President
- Tzvi Palash, Chief Operating Officer
- Shai Lankry, Chief Financial & Accounting Officer
- Tony Peled, Chief Scientific Officer, Vice President-R&D
When did Gamida Cell IPO?
(GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.
Who are Gamida Cell's major shareholders?
Gamida Cell's stock is owned by many different of retail and institutional investors. Top institutional investors include Rock Springs Capital Management LP (4.13%), Noked Capital LTD (0.84%), EcoR1 Capital LLC (0.22%), Bank Hapoalim BM (0.16%) and Royal Bank of Canada (0.06%).
Which institutional investors are buying Gamida Cell stock?
GMDA stock was acquired by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Noked Capital LTD, EcoR1 Capital LLC, Bank Hapoalim BM and Royal Bank of Canada.
How do I buy shares of Gamida Cell?
Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Gamida Cell's stock price today?
One share of GMDA stock can currently be purchased for approximately $4.45.
How big of a company is Gamida Cell?
Gamida Cell has a market capitalization of $107.78 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell.
What is Gamida Cell's official website?
How can I contact Gamida Cell?
Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]
MarketBeat Community Rating for Gamida Cell (NASDAQ GMDA)
MarketBeat's community ratings are surveys of what our community members think about Gamida Cell and other stocks. Vote "Outperform" if you believe GMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
